On September 22, 2021 CG Oncology, Inc. reported that it has entered into a clinical trial collaboration agreement to evaluate the combination of CG Oncology’s investigational oncolytic immunotherapy CG0070, with Roche’s atezolizumab, an anti-PD-L1 (programmed death-ligand 1) therapy (Press release, CG Oncology, SEP 22, 2021, View Source [SID1234590140]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1/2 clinical trial will evaluate the safety and efficacy of this novel immunotherapy combination in patients with various advanced solid tumors yet to be disclosed. CG Oncology will sponsor the study and Roche will provide atezolizumab.

CG0070, CG Oncology’s lead immuno-oncology candidate, is in an ongoing Phase 3 monotherapy study and has been administered in over 100 patients to date for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). CG0070 is based on a modified adenovirus type 5 backbone that contains a cancer-selective promoter and a GM-CSF transgene, destroying various cancer cells, including bladder tumor cells, through their defective retinoblastoma (Rb) pathway.

"We are pleased to enter into this collaboration agreement with Roche," said Arthur Kuan, CEO of CG Oncology. "We are excited to initiate this important clinical trial with our lead oncolytic immunotherapy, CG0070, in combination with atezolizumab to evaluate the potential synergy of these two immunotherapies in cancer."

Additional details of the collaboration were not disclosed.